Patent ID: 8188131

Claim:
A method of treating a hearing impairment or imbalance disorder associated with loss of auditory hair cells in a patient in need of such treatment, the method comprising selecting the patient in need of treatment, and administering to the patient a therapeutically effective amount of a pharmaceutical composition comprising a compound having the following formula: wherein: each of R 118 , R 119 , R 120 , and R 121 is, independently selected from H, halo, OH, CN, NO 2 , C 1 -C 3 alkyl, C 1 -C 3 haloalkyl, alkoxy, and C 1 -C 3 haloalkoxy; R 122 is hydrogen or —Z—R a ; wherein: Z is O or a bond; and R a is: (i) C 1 -C 6 alkyl or C 1 -C 6 haloalkyl, each of which is optionally substituted with from 1-3 R b ; or (ii) C 3 -C 10 cycloalkyl, C 3 -C 10 cycloalkenyl, each of which is optionally substituted with from 1-5 R c ; or (iii) C 7 -C 11 aralkyl, or heteroaralkyl including 6-11 atoms, each of which is optionally substituted with from 1-5 R c ; (iv) C 6 -C 10 aryl or heteroaryl including 5-10 atoms, each of which is optionally substituted with from 1-5 R d ; R 123 is: (i) hydrogen; or (ii) C 1 -C 6 alkyl or C 1 -C 6 haloalkyl, each of which is optionally substituted with from 1-3 R b ; or (iii) C 6 -C 10 aryl or heteroaryl including 5-10 atoms, each of which is optionally substituted with from 1-5 R d ; or (iv) C 7 -C 11 aralkyl, or heteroaralkyl including 6-11 atoms, each of which is optionally substituted with from 1-5 R c ; or (v) —(C 1 -C 6 alkyl)-Z 1 —(C 6 -C 10 aryl), wherein Z 1 is O, S, NH, or N(CH 3 ); the alkyl portion is optionally substituted with from 1-3 R b ; and the aryl portion is optionally substituted with from 1-5 R d ; or (vi) —(C 1 -C 6 alkyl)-Z 2 -(heteroaryl including 5-10 atoms), wherein Z 2 is O, S, NH, or N(CH 3 ); the alkyl portion is optionally substituted with from 1-3 R b ; and the heteroaryl portion is optionally substituted with from 1-5 R d ; or (vii) —(C 1 -C 6 alkyl)-Z 3 —(C 3 -C 10 cycloalkyl), wherein Z 3 is O, S, NH, or N(CH 3 ); the alkyl portion is optionally substituted with from 1-3 R b ; and the cycloalkyl portion is optionally substituted with from 1-5 R c ; R b at each occurrence is, independently: (i) NH 2 ; NH(C 1 -C 3 alkyl); N(C 1 -C 3 alkyl) 2 ; hydroxy; C 1 -C 6 alkoxy or C 1 -C 6 haloalkoxy; or (ii) C 3 -C 2 cycloalkyl optionally substituted with from 1-3 substituents independently selected from C 1 -C 6 alkyl, NH 2 ; NH(C 1 -C 3 alkyl); N(C 1 -C 3 alkyl) 2 ; hydroxy; C 1 -C 6 alkoxy or C 1 -C 6 haloalkoxy; R c at each occurrence is, independently: (i) halo; NH 2 ; NH(C 1 -C 3 alkyl); N(C 1 -C 3 alkyl) 2 ; hydroxy; C 1 -C 6 alkoxy; C 1 -C 6 haloalkoxy; or oxo; or (ii) C 1 -C 6 alkyl or C 1 -C 6 haloalkyl; and R d at each occurrence is, independently: (i) halo; NH 2 ; NH(C 1 -C 3 alkyl); N(C 1 -C 3 alkyl) 2 ; hydroxy; C 1 -C 6 alkoxy or C 1 -C 6 haloalkoxy; nitro; —NHC(O)(C 1 -C 3 alkyl); or cyano; or (ii) C 1 -C 6 alkyl or C 1 -C 6 haloalkyl; or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.